Anxiety disorders and depression are different, but people with depression often experience symptoms similar to those of an anxiety disorder, such as nervousness, irritability, and problems sleeping and concentrating. But each disorder has its own causes and its own emotional and behavioral symptoms. Anxiety disorders and depression are common psychiatric disorders that affect a large number of people during their lifetime. According to the WHO, by 2020, depression and anxiety disorders including stress related psychiatric conditions would rival cardiovascular diseases as the major health disorder with the highest disease burden. Currently, medications together with psychotherapy are the best treatment approach for patients suffering from depression and anxiety disorders.
The global anxiety disorders and depression treatment market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global anxiety disorders and depression treatment market segmentation is based on drug class (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake, atypical antipsychotics, tricyclic antidepressants, tetracyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, anticonvulsants).
The global anxiety disorders and depression treatment market report also provides detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.The global anxiety disorders and depression treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the anxiety disorders and depression treatment market and profiled in this report include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline plc, H. Lundbeck A/S, Pfizer, Inc., Merck & Co., Inc. and Sanofi S.A.